NICE draft say No to BMS and Novartis's leukaemia treatments
This article was originally published in Scrip
Executive Summary
NICE, the health technology appraisal institute for England and Wales, has initially rejected both Bristol-Myers Squibb's Sprycel (dasatinib) and Novartis's Tasigna (nilotinib) for some NHS patients with chronic myeloid leukaemia (CML). The institute said weak data cast doubt over the drugs' effectiveness.